PAREXEL has established an alliance with University Hospitals Bristol National Health Service (NHS) Foundation Trust (UH Bristol), one of the largest specialist teaching and research hospital trusts in the UK. The agreement with UH Bristol, expands PAREXEL’s team of experts and hospital-based early phase units, providing clients with access to diverse patient populations worldwide in key therapeutic areas. UH Bristol employs more than 7,900 people, and delivers more than 100 different clinical services from a group of nine hospitals.

"Our extensive, relevant experience and in-depth expertise, as well as global access to suitable patient populations, all contribute to our ability to assist clients with ever more complex early-phase trial design and execution. In doing so, our focus is to provide more efficient delivery of better, faster go/no-go decisions," said Sy Pretorius, M.D., M.S., M.B.A., corporate vice president and worldwide head of Early Phase. "UH Bristol is an ideal alliance for us because of its experience in conducting clinical research, access to substantial patient populations, and work across multiple therapeutic areas."

Professor David Wynick, a research director at UH Bristol, said, "We believe this alliance furthers our objectives to develop collaborative and consultative research partnerships and support research of national and international excellence and innovation. We look forward to working with PAREXEL to expand our research portfolio for the benefit of patients."